Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2161 to 2175 of 8314 results

  1. Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development Reference number: GID-TA11019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    In development Reference number: GID-TA11199 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    In development Reference number: GID-TA11425 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development Reference number: GID-TA10911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

    Technology appraisal guidance
    In development